AR072596A1 - Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico - Google Patents
Un complejo proteico que comprende una proteina dimerica y un polimero no peptidicoInfo
- Publication number
- AR072596A1 AR072596A1 ARP090102798A ARP090102798A AR072596A1 AR 072596 A1 AR072596 A1 AR 072596A1 AR P090102798 A ARP090102798 A AR P090102798A AR P090102798 A ARP090102798 A AR P090102798A AR 072596 A1 AR072596 A1 AR 072596A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- physiologically active
- protein complex
- polypeptides
- active polypeptide
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 10
- 108090000623 proteins and genes Proteins 0.000 title abstract 10
- 229920000642 polymer Polymers 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 9
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
Se describe un complejo proteico, que comprende un polipéptido fisiologicamente activo, una proteína dimérica y un polímero no peptídico que tiene tres extremos funcionales (3 brazos), con el enlace tanto del polipéptido fisiologicamente activo como de la proteína dimérica con el polímero no peptídico de 3 brazos mediante respectivas uniones covalentes. El complejo proteico garantiza la actividad de la accion y la bioestabilidad prolongada de un polipéptido fisiologicamente activo. Al tener la capacidad de mantener la bioactividad de los polipéptidos fisiologicamente activos o de los péptidos, de mejorar la semivida sérica de los polipéptidos o péptidos, el complejo proteico puede aplicarse al desarrollo de formulaciones de liberacion sostenida de diversas drogas con polipéptidos fisiologicamente activos. Además, utiliza materias primas que incluyen polipéptidos fisiologicamente activos sin pérdida significativa y, en consecuencia, aumenta el rendimiento de la produccion. También puede ser fácil de purificar. Un método para preparar un complejo proteico y una composicion farmacéutica. Reivindicacion 2: El complejo proteico de acuerdo con la reivindicacion 1, en el cual la proteína dimérica es un dominio del Fc de la inmunoglobulina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080071766 | 2008-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072596A1 true AR072596A1 (es) | 2010-09-08 |
Family
ID=41570742
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102798A AR072596A1 (es) | 2008-07-23 | 2009-07-23 | Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico |
ARP170102463A AR109513A2 (es) | 2008-07-23 | 2017-09-06 | Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102463A AR109513A2 (es) | 2008-07-23 | 2017-09-06 | Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende |
Country Status (22)
Country | Link |
---|---|
US (3) | US9636420B2 (es) |
EP (1) | EP2300501B1 (es) |
JP (1) | JP5563572B2 (es) |
KR (1) | KR101200659B1 (es) |
CN (1) | CN102112493B (es) |
AR (2) | AR072596A1 (es) |
AU (1) | AU2009274738B2 (es) |
BR (1) | BRPI0916326A2 (es) |
CA (1) | CA2731546C (es) |
CL (1) | CL2011000079A1 (es) |
ES (1) | ES2523043T3 (es) |
HK (1) | HK1154023A1 (es) |
IL (1) | IL210466A (es) |
MX (1) | MX2011000861A (es) |
MY (1) | MY151184A (es) |
NZ (1) | NZ590358A (es) |
PE (1) | PE20110221A1 (es) |
RU (1) | RU2483081C2 (es) |
TW (1) | TWI388570B (es) |
UA (1) | UA101670C2 (es) |
WO (1) | WO2010011096A2 (es) |
ZA (1) | ZA201100157B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1759001E (pt) | 2004-04-21 | 2011-07-12 | Enobia Pharma Inc | Conjugados de libertação óssea e método de utilização dos mesmos para direccionar proteínas ao osso |
BRPI0916326A2 (pt) | 2008-07-23 | 2020-08-25 | Hanmi Holdings Co., Ltd. | complexo polipeptídico compreendendo polímero não-peptidil com três extremidades funcionais |
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
AU2011249783B9 (en) | 2010-05-06 | 2014-11-06 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies |
US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
KR20120002129A (ko) * | 2010-06-30 | 2012-01-05 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
JP6105477B2 (ja) * | 2010-11-05 | 2017-03-29 | ライナット ニューロサイエンス コーポレイション | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 |
EP2658979B1 (en) | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
SG10201811256QA (en) | 2011-06-28 | 2019-01-30 | Inhibrx Lp | Serpin fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
WO2013007563A1 (en) * | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
RU2622077C2 (ru) * | 2011-09-05 | 2017-06-09 | Ханми Сайенс Ко., Лтд. | Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
JP2015502741A (ja) | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | 低比重リポタンパク質関連タンパク質6(lrp6)−半減期延長構築物 |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
KR101665009B1 (ko) * | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
WO2013148871A1 (en) * | 2012-03-28 | 2013-10-03 | Amylin Pharmaceuticals, Llc | Engineered polypeptides |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
MX367817B (es) * | 2013-03-05 | 2019-09-06 | Hanmi Pharm Ind Co Ltd | Procedimiento de preparación mejorado para producción de alto rendimiento de conjugado polipeptídico fisiológicamente activo. |
KR101479937B1 (ko) * | 2013-05-24 | 2015-01-12 | 주식회사 에스에프에이 | 글라스와 마스크의 정렬장치 |
AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
CA3012994C (en) | 2013-07-31 | 2020-10-20 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
HU231358B1 (hu) * | 2014-03-31 | 2023-03-28 | Hanmi Pharm. Co., Ltd | Eljárás fehérjék és peptidek oldhatóságának javítására immunoglobulin Fc fragmentum kapcsolás alkalmazása révén |
CN106456798B (zh) | 2014-04-25 | 2021-02-12 | 瑞纳神经科学公司 | 具有高药物负载的抗体-药物缀合物 |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
RU2708068C2 (ru) | 2014-12-05 | 2019-12-04 | Алексион Фармасьютикалз, Инк. | Лечение судорог с использованием рекомбинантной щелочной фосфатазы |
CA2973883A1 (en) | 2015-01-28 | 2016-08-04 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
EP3303380B1 (en) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
US11123436B2 (en) | 2015-07-24 | 2021-09-21 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
MX2018002121A (es) | 2015-08-17 | 2018-06-18 | Alexion Pharma Inc | Elaboracion de fosfatasas alcalinas. |
WO2017052329A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物 |
JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ(tnsalp)酵素補充療法に有効な投薬計画の特定 |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
KR20220162816A (ko) | 2016-04-01 | 2022-12-08 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타아제로 근육 약화의 치료 |
EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
WO2018035420A1 (en) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
US11224637B2 (en) | 2017-03-31 | 2022-01-18 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー/エス | オリゴマー伸長インスリン−Fcコンジュゲート |
CN111315767A (zh) | 2017-08-22 | 2020-06-19 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
CN107540748B (zh) * | 2017-09-15 | 2020-07-14 | 北京伟杰信生物科技有限公司 | 长效重组猪fsh融合蛋白及其制备方法与应用 |
KR101974305B1 (ko) * | 2018-02-14 | 2019-04-30 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
EP3773684A1 (en) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
US11267858B2 (en) * | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
WO2022166720A1 (zh) * | 2021-02-05 | 2022-08-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
DK0835939T3 (da) | 1990-06-28 | 2006-03-13 | Sanofi Aventis Deutschland | Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse |
AU660662B2 (en) | 1991-02-08 | 1995-07-06 | Progenics Pharmaceuticals, Inc. | CD4-gamma2 and CD4-IgG2 chimeras |
SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
EP0596011A1 (en) * | 1991-07-19 | 1994-05-11 | Hybritech Incorporated | Trifunctional compounds having specificity for multi-drug resistant cells |
EP0533006A1 (en) | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
US5399671A (en) | 1992-11-18 | 1995-03-21 | Kluger; Ronald | Specifically crosslinked hemoglobin with free functionality |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1121382B9 (en) | 1998-10-16 | 2007-07-04 | Biogen Idec MA Inc. | Interferon-beta fusion proteins and uses |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
AU782496B2 (en) | 1999-07-13 | 2005-08-04 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
PL393178A1 (pl) | 2000-12-07 | 2011-02-14 | Eli Lilly And Company | Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulino-niezależną i kompozycja farmaceutyczna do leczenia pacjentów z otyłością |
US7737260B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
WO2003049684A2 (en) * | 2001-12-07 | 2003-06-19 | Centocor, Inc. | Pseudo-antibody constructs |
US20040023848A1 (en) * | 2002-02-27 | 2004-02-05 | Thomas Boehm | Compositions for the treatment, prevention, and diagnosis of gastrointestinal and other infections |
KR20050086907A (ko) | 2002-12-13 | 2005-08-30 | 미트라 메디칼 테크놀로지 에이비 | 3중 작용 시약에 의해 연결된 작동성 및 친화성 기능을갖는 항림프종 표적화제 |
BRPI0515118A (pt) * | 2004-08-31 | 2008-07-01 | Pharmacia & Upjohn Co Llc | conjugados de hormÈnio do crescimento humano com polietileno glicol |
CN101163506B (zh) * | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
WO2006076471A2 (en) | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CN101258164B (zh) * | 2005-08-16 | 2013-05-01 | 韩美科学株式会社 | 用于大量生产缺失起始甲硫氨酸残基的免疫球蛋白Fc区的方法 |
CN104090095B (zh) * | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
WO2007132956A1 (en) * | 2006-05-12 | 2007-11-22 | Dong-A Pharm.Co., Ltd. | Polyethylene glycol-interferon alpha conjugate |
CA2662981A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
WO2008095004A2 (en) * | 2007-01-31 | 2008-08-07 | Affymax, Inc. | Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules |
BRPI0916326A2 (pt) * | 2008-07-23 | 2020-08-25 | Hanmi Holdings Co., Ltd. | complexo polipeptídico compreendendo polímero não-peptidil com três extremidades funcionais |
-
2009
- 2009-07-23 BR BRPI0916326-3A patent/BRPI0916326A2/pt not_active Application Discontinuation
- 2009-07-23 PE PE2011000032A patent/PE20110221A1/es active IP Right Grant
- 2009-07-23 MY MYPI20110132 patent/MY151184A/en unknown
- 2009-07-23 CA CA2731546A patent/CA2731546C/en active Active
- 2009-07-23 US US13/055,406 patent/US9636420B2/en active Active
- 2009-07-23 JP JP2011519993A patent/JP5563572B2/ja active Active
- 2009-07-23 UA UAA201100651A patent/UA101670C2/ru unknown
- 2009-07-23 TW TW98124944A patent/TWI388570B/zh not_active IP Right Cessation
- 2009-07-23 EP EP09800577.0A patent/EP2300501B1/en active Active
- 2009-07-23 KR KR1020090067449A patent/KR101200659B1/ko active IP Right Grant
- 2009-07-23 ES ES09800577.0T patent/ES2523043T3/es active Active
- 2009-07-23 NZ NZ590358A patent/NZ590358A/en not_active IP Right Cessation
- 2009-07-23 CN CN200980127997.4A patent/CN102112493B/zh active Active
- 2009-07-23 AR ARP090102798A patent/AR072596A1/es active IP Right Grant
- 2009-07-23 AU AU2009274738A patent/AU2009274738B2/en active Active
- 2009-07-23 RU RU2011102446/10A patent/RU2483081C2/ru active
- 2009-07-23 MX MX2011000861A patent/MX2011000861A/es active IP Right Grant
- 2009-07-23 WO PCT/KR2009/004114 patent/WO2010011096A2/en active Application Filing
-
2011
- 2011-01-05 IL IL210466A patent/IL210466A/en active IP Right Grant
- 2011-01-06 ZA ZA2011/00157A patent/ZA201100157B/en unknown
- 2011-01-13 CL CL2011000079A patent/CL2011000079A1/es unknown
- 2011-08-08 HK HK11108263.0A patent/HK1154023A1/xx not_active IP Right Cessation
-
2015
- 2015-10-02 US US14/873,321 patent/US10071171B2/en active Active
-
2017
- 2017-09-06 AR ARP170102463A patent/AR109513A2/es unknown
-
2018
- 2018-08-07 US US16/057,454 patent/US11040110B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072596A1 (es) | Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico | |
CY1119243T1 (el) | Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf | |
Duan et al. | Constructing tunable nanopores and their application in drug delivery | |
UA106869C2 (uk) | Поліпептид ace2 | |
NO2017028I1 (no) | eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
CY1121042T1 (el) | Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως | |
EA200801460A1 (ru) | Рекомбинантные моновалентные антитела и способы их получения | |
BRPI0518793A2 (pt) | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica | |
ATE509634T1 (de) | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel | |
AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
BR0010750A (pt) | Peptìdeos insulinotrópicos de longa duração | |
DE602005009175D1 (de) | Gelzusammensetzung mit geladenen polymeren | |
EA201890389A3 (ru) | Композиции конъюгата xten и способы их получения | |
ATE385806T1 (de) | Fusionsproteine | |
DE602006003935D1 (de) | Verwendung von Stärke mit abgespaltenen Seitenketten in der Extrudierung / Spheronisierung von pharmazeutischen Pellets | |
BRPI0408331B8 (pt) | conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo | |
CY1110973T1 (el) | Βελτιωμενα διμερη sgp130fc | |
PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
UY31123A1 (es) | Proteinas de fusion natriureticas | |
EA200601905A1 (ru) | Микрокапсулы с замедленным высвобождением, основанные на сополимере лактида и гликолида, включающие полипептид и сахар | |
BRPI0620436A8 (pt) | compostos miméticos de lisina modificados, composição farmacêutica e uso | |
DE602007004120D1 (de) | Spezifische monokonjugate von g-csf | |
WO2006076594A3 (en) | Antibodies and fc fusion proteins with altered immunogenicity | |
MY157772A (en) | Antibody formulation | |
AR066199A1 (es) | Metodo para reducir la concentracion del peptido amiloide beta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |